Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. META
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results

Adverum Biotechnologies (ADVM) Misses Q1 EPS by 4c

May 28, 2020 4:02 PM EDT

Adverum Biotechnologies (NASDAQ: ADVM) reported Q1 EPS of ($0.31), $0.04 worse than the analyst estimate of ($0.27).

Im thankful for the strong commitment and resilience our employees have exhibited towards advancing our pipeline despite the challenges of COVID 19, said Leone Patterson, president and chief executive officer, Adverum... More